middle.news
Clinuvel Advances Peptide Drug Delivery with VLRX-L Preclinical Dosing
8:53am on Monday 12th of January, 2026 AEDT
•
Pharmaceuticals
Read Story
Clinuvel Advances Peptide Drug Delivery with VLRX-L Preclinical Dosing
8:53am on Monday 12th of January, 2026 AEDT
Key Points
Dosing commenced in preclinical study of VLRX-L peptide platform
Platform designed for controlled-release of melanocortin-based drugs
Developed at Clinuvel’s Singapore VALLAURIX RD&I Centre
Preliminary safety and kinetics results expected H2 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clinuvel Pharmaceuticals (ASX:CUV)
OPEN ARTICLE